Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Antisense technology is beginning to deliver on the broad promise of the technology. Ten
RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double …

RNA-targeted therapies represent a platform for drug discovery involving chemically
modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif …

Long noncoding RNAs (lncRNAs), which are encoded by a vast less explored region of the
human genome, may hold missing drivers of cancer and have gained attention recently as a …

Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …

Antisense oligonucleotides (ASOs) are used to selectively inhibit the translation of disease-
associated genes via Ribonuclease H (RNaseH)-mediated cleavage or steric hindrance …

Seizures result from hypersynchronous, abnormal firing of neuronal populations and are the
primary clinical symptom of the epilepsies. Brain tissue from animal models and patients …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the
lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC) …

Long noncoding RNAs (lncRNA) are involved in tumorigenesis and drug resistance.
However, the roles and underlying mechanisms of lncRNAs in colorectal cancer are still …